TFX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -17.18% compared to Teleflex's net margin of 12.41%. Teleflex's return on equity of 1.57% beat Boston Scientific's return on equity of 8.96%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 23.43%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 21.23%. Given that Teleflex has higher upside potential than Boston Scientific, analysts believe Teleflex is more attractive than Boston Scientific.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Teleflex's net income of -$136.7M is lower than Boston Scientific's net income of $566M. Notably, Teleflex's price-to-earnings ratio is 95.97x while Boston Scientific's PE ratio is 76.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.11x versus 8.46x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -17.18% compared to Teleflex's net margin of 28.41%. Teleflex's return on equity of 1.57% beat Intuitive Surgical's return on equity of 15.6%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 23.43%. On the other hand Intuitive Surgical has an analysts' consensus of $632.53 which suggests that it could grow by 32.67%. Given that Intuitive Surgical has higher upside potential than Teleflex, analysts believe Intuitive Surgical is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Teleflex's net income of -$136.7M is lower than Intuitive Surgical's net income of $685.7M. Notably, Teleflex's price-to-earnings ratio is 95.97x while Intuitive Surgical's PE ratio is 74.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.11x versus 20.66x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of -17.18% compared to Teleflex's net margin of -25.21%. Teleflex's return on equity of 1.57% beat QuidelOrtho's return on equity of -58.1%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 23.43%. On the other hand QuidelOrtho has an analysts' consensus of $51.14 which suggests that it could grow by 43.66%. Given that QuidelOrtho has higher upside potential than Teleflex, analysts believe QuidelOrtho is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.097, suggesting its less volatile than the S&P 500 by 90.311%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than QuidelOrtho quarterly revenues of $707.8M. Teleflex's net income of -$136.7M is higher than QuidelOrtho's net income of -$178.4M. Notably, Teleflex's price-to-earnings ratio is 95.97x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.11x versus 0.86x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -17.18% compared to Teleflex's net margin of 17.38%. Teleflex's return on equity of 1.57% beat West Pharmaceutical Services's return on equity of 18.15%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 23.43%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 27.89%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1%. West Pharmaceutical Services offers a yield of 0.37% to investors and pays a quarterly dividend of $0.21 per share. Teleflex pays 91.2% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Teleflex's net income of -$136.7M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Teleflex's price-to-earnings ratio is 95.97x while West Pharmaceutical Services's PE ratio is 33.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.11x versus 5.70x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.